Endocrine Abstracts

Background: Real life implementation studies performed in different settings/populations proved that lifestyle interventions in prevention of DM2 can be effective. However, little is known about long term results of these translational studies and determinants of the outcomes.Aim: The purpose of this study was to examine the maintenance of diabetes type 2 risk factor during 3 year follow-up and to examine determinants of long term outcomes.<p class="...

Composite pheochromocytomas (CP) are rare and constitute 3% of pheochromocytomas. So far, less than 100 cases were described in the literature. We present a case of 60 years old man. He was admitted to ER department due to severe bone pain around chest, ribs and vertebra. CT scan showed expansive, 100x87 mm, non-homogenic left adrenal gland tumour as well as metastatic bone lesions. The 24-hour urinary fractionated metanephrines were significantly elevated - 86195 ug/24h (norm...

Introduction: According to the literature, the CRH test has the highest specificity in excluding ECS (ACTH 93.9%, cortisol 89.4%). A combination of the high dose dexamethasone test (HDDST) and CRH/desmopressin test (CRH/desmopressinT) is used to increase the discriminatory capacity in ACTH-dependent CS.Objectives: This study aims to investigate the response to dynamic tests in ECS patients.Methods: 35 consecutive ECS patients were ...

Pasireotide is a a synthetic polypeptide second-generation somatostatin analogue that can be used in the treatment of GH- and ACTH- secreting pituitary neuroendocrine tumors (PitNETs), however, there are single reports of pasireotide treatment in other subtype of PitNETs. We present a case series of aggressive, giant PitNETs treated with pasireotide alone or as multimodal therapy.Case 1: A 33-year-old male reported to the Clinic due to severe headaches a...

Introduction: Liver Steatosis (LS) can be one of the metabolic complications of Cushing Syndrome (CS). The data on the impact of cortisol on liver function are very limited, according to one study the prevalence of LS in CS is 20%. However, the frequency seems to be much higher. Hepatic Steatosis Index (HSI) predicts LS based on ALT, AST, BMI, sex and co-existence of diabetes mellitus/impaired glucose intolerance. It can identify candidates for further liver examinations.<...

Cushing Syndrome (CS) is associated with a 18-fold higher risk of venous thromboembolism (VTE) when compared to the general population with the similar demographic characteristics. Despite numerous studies on hypercoagulability in CS, the unequivocal recommendations regarding timing and dosing of thromboprophylaxis in hypercortisolism are still lacking. We present a case series of patients with CS and VTE, hospitalized in the Endocrinology Department of University Hospital in ...

Introduction: Liver Steatosis(LS) can be one of the metabolic complications of Cushing Syndrome(CS). The data on the impact of cortisol on liver function are very limited, and there is only one study reporting a prevalence of LS of roughly 20%. Hepatic Steatosis Index (HSI) predicts LS based on ALT, AST, BMI, sex and co-existence of diabetes mellitus/impaired glucose intolerance.Objectives: To evaluate the prevalence of LS in patients with CS at the time...

Introduction: The data on giant prolactinomas (the rare (3%) subtype of lactotroph PitNET (≥40 mm) ), often causing clinical and therapeutic difficulties are scarce.Aim: We studied clinical/biochemical and treatment outcomes differences between giant and macroprolactinomas.Materials and methods: Consecutive patients with giant prolactinomas ≥40 mm (GP) and macroprolactinomas >10 mm<40 mm (MP) treated in the tert...

Somatostatin analogues (SSA) are used to treat different forms of hyperinsulinemic hypoglycemia (HH) in children and adults and therapeutic effect is achieved by suppressing insulin secretion from pancreatic β-cells by complex mechanisms. These treatments might be associated with several side effects, can even cause the worsening of severity of hypoglycemia. This is a report of the treatment of HH with SSA in patient with Activating Mutation (GCK), c.295T>C (p.Trp99Ar...

Introduction: Somatotroph Pituitary Neuroendocrine Tumor’s (sPitNET) signal intensity in T2-weighted MR images (SI) was reported as prognostic marker for tumor’s aggressiveness and poor response to 1st generation somatostatin analogs (SSA). Tumors are arbitrary divided into 3 groups: hyperintensive (HYPER), isointensive (ISO) and hypointensive (HYPO). Aim: Our aim was to quantitatively assess SI of sPitNETs and investigate its clinic...